Epidermal Growth Factor Receptor (EGFR) Status Based Gefitinib Neoadjuvant Therapy in Non Small Cell Lung Cancer (NSCLC)

Phase II Study of EGFR Status Based Gefitinib Neoadjuvant Therapy in NSCLC Patients

This study aims to investigate the efficacy and safety of gefitinib as neoadjuvant therapy in stage IIIA NSCLC patients.

Inclusion Criteria:

• Patients pathological diagnosed with NSCLC,with EGFR sensitive mutation;
• Stage IIIA patients with technical operable disease evaluated by image and lab results;
• Patients without chemotherapy or targeted-therapy before;
• Inform Consent.

Exclusion Criteria:

• Patients with malignant tumor other than lung cancer;
• Patients with other diseases such as cardiovascular disease that may hamper follow up;
• Patients that may not coordinate well,judged by researcher.